Tumor response after low-dose preoperative radiotherapy combined with chemotherapy for squamous cell esophageal carcinoma

Anticancer Research

Volumn 33, Issue 3, 2013, Pages 1157-1162

  Kobayashi, Noriko ^a   Nakayama, Hidetsugu ^a   Osaka, Yoshiaki ^a   Tachibana, Shingo ^a   Nogi, Sachika ^a   Tajima, Yu ^a   Okubo, Mitsuru ^a   Mikami, Ryuji ^a   Kanesaka, Naoto ^a   Sugahara, Shinji ^a   Hoshino, Sumito ^a   Tsuchida, Akihiko ^a   Tokuuye, Koichi ^a  

^a TOKYO MEDICAL UNIVERSITY   (Japan)

Author keywords

Chemoradiotherapy; Esophageal carcinoma; Squamous cell; Surgery

Indexed keywords

CISPLATIN; FLUOROURACIL;

ADULT; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER STAGING; CANCER SURGERY; CLINICAL ARTICLE; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; LOW ENERGY RADIATION; MALE; MICROSCOPY; OVERALL SURVIVAL; PREOPERATIVE RADIOTHERAPY; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RADIATION DOSE; TREATMENT RESPONSE;

ADULT; AGED; CARCINOMA, SQUAMOUS CELL; CHEMORADIOTHERAPY; ESOPHAGEAL NEOPLASMS; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; RADIATION DOSAGE;

EID: 84875882564     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. Matsuda A, Marugame T, Shibata A, Katanoda K, Sobue T and Nishimoto H: Cancer incidence and incidence rates in Japan in 2007: A study of 21 population-based cancer registries in the Monitoring of Cancer Incidence in Japan (MCIJ) project. Jpn J Clin Oncol 2013 Jan 7 (Epub ahead of print).
2. Ando N, Kato H, Igaki H, Shinoda M, Ozawa S, Shimizu H, Nakamura T, Yabusaki H, Aoyama N, Kurita A, Ikeda K, Kanda T, Tsujinaka T, Nakamura K and Fukuda H: A Randomized Trial Comparing Postoperative Adjuvant Chemotherapy with Cisplatin and 5-Fluorouracil Versus Preoperative Chemotherapy for Localized Advanced Squamous Cell Carcinoma of the Thoracic Esophagus (JCOG9907). Ann Surg Oncol 19: 68-74, 2012.
3. Bosset JF, Gignoux M, Triboulet JP, Tiret E, Mantion G, Elias D, Lozach P, Ollier JC, Pavy JJ, Mercier M and Sahmoud T: Chemoradiotherapy followed by surgery compared with surgery alone in squamouscell cancer of the esophagus. N Engl J Med 337: 161-167, 1997.
4. Burmeister BH, Smithers BM, Gebski V, Fitzgerald L, Simes RJ, Devitt P, Ackland S, Gotley DC, Joseph D, Millar J, North J, Walpole ET and Denham JW: Surgery alone versus chemoradiotherapy followed by surgery for resectable cancer of the oesophagus: A randomised controlled phase III trial. Lancet Oncol 6: 659-668, 2005.
5. Urba SG, Orringer MB, Turrisi A, Iannettoni M, Forastiere A and Strawderman M: Randomized trial of preoperative chemoradiation versus surgery alone in patients with locoregional esophageal carcinoma. J Clin Oncol 19: 305-313, 2001.
6. Fiorica F, Di Bona D, Schepis F, Licata A, Shahied L, Venturi A, Falchi AM, Craxi A and Camma C: Preoperative chemoradiotherapy for oesophageal cancer: A systematic review and meta-analysis. Gut 53: 925-930, 2004.
7. Gebski V, Burmeister B, Smithers BM, Foo K, Zalcberg J and Simes J: Survival benefits from neoadjuvant chemoradiotherapy or chemotherapy in oesophageal carcinoma: A meta-analysis. Lancet Oncol 8: 226-234, 2007.
8. Urschel JD and Vasan H: A meta-analysis of randomized controlled trials that compared neoadjuvant chemoradiation and surgery to surgery alone for resectable esophageal cancer. Am J Surg 185: 538-543, 2003.
9. Osaka Y, Takagi Y, Tsuchida A, Hoshino S, Tachibana S, Shinohara M and Aoki T: Concurrent preoperative chemoradiotherapy for stage III or IV esophageal squamous carcinoma. Oncol Reports 12: 1121-1126, 2004.
10. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, van Galbbeke M, van Oosterom AT, Christian MC and Gwyther SG: New guidelines to evaluate the response to treatmetn in solid tumors. J Natl Cancer Inst 92: 205-212, 2000.
11. National Cancer Institute: Common Terminology Criteria for Adverse Events (CTCAE) v.4 2009 URL http://evs.nci.nih.gov/ftp1/CTCAE/About.html
12. Berger AC, Farma J, Scott WJ, Freedman G, Weiner L, Cheng JD, Wang H and Goldberg M: Complete response to neoadjuvant chemoradiotherapy in esophageal carcinoma is associated with significantly improved survival. J Clin Oncol 23: 4330-4337, 2005.
13. Hofstetter W, Swisher SG, Correa AM, Hess K, Putnam JB, Jr., Ajani JA, Dolormente M, Francisco R, Komaki RR, Lara A, Martin F, Rice DC, Sarabia AJ, Smythe WR, Vaporciyan AA, Walsh GL and Roth JA: Treatment outcomes of resected esophageal cancer. Ann Surg 236: 376-384; discussion 384-375, 2002.
14. Mariette C, Finzi L, Fabre S, Balon JM, Van Seuningen I and Triboulet JP: Factors predictive of complete resection of operable esophageal cancer: a prospective study. Ann Thoraci Surg 75: 1720-1726, 2003.
15. Ishida K, Ando N, Yamamoto S, Ide H and Shinoda M: Phase II study of cisplatin and 5-fluorouracil with concurrent radiotherapy in advanced squamous cell carcinoma of the esophagus: A Japan Esophageal Oncology Group (JEOG)/Japan Clinical Oncology Group trial (JCOG9516). Jpn J Clin Oncol 34: 615-619, 2004.
16. Le Prise E, Etienne PL, Meunier B, Maddern G, Ben Hassel M, Gedouin D, Boutin D, Campion JP and Launois B: A randomized study of chemotherapy, radiation therapy, and surgery versus surgery for localized squamous cell carcinoma of the esophagus. Cancer 73: 1779-1784, 1994.
17. Walsh TN, Noonan N, Hollywood D, Kelly A, Keeling N and Hennessy TP: A comparison of multimodal therapy and surgery for esophageal adenocarcinoma. N Eng J Med 335: 462-467, 1996.
18. Tepper J, Krasna MJ, Niedzwiecki D, Hollis D, Reed CE, Goldberg R, Kiel K, Willett C, Sugarbaker D and Mayer R: Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy and surgery compared with surgery alone for esophageal cancer: CALGB 9781. J Clin Oncol 26: 1086-1092, 2008.
19. van Hagen P, Hulshof MC, van Lanschot JJ, Steyerberg EW, van Berge Henegouwen MI, Wijnhoven BP, Richel DJ, Nieuwenhuijzen GA, Hospers GA, Bonenkamp JJ, Cuesta MA, Blaisse RJ, Busch OR, ten Kate FJ, Creemers GJ, Punt CJ, Plukker JT, Verheul HM, Spillenaar Bilgen EJ, van Dekken H, van der Sangen MJ, Rozema T, Biermann K, Beukema JC, Piet AH, van Rij CM, Reinders JG, Tilanus HW and van der Gaast A; CROSS Group: Preoperative chemoradiotherapy for esophageal or junctional cancer. N Engl J Med 366: 2074-2084, 2012.
20. Stahl M, Stuschke M, Lehmann N, Meyer HJ, Walz MK, Seeber S, Klump B, Budach W, Teichmann R, Schmitt M, Schmitt G, Franke C and Wilke H: Chemoradiation with and without surgery in patients with locally advanced squamous cell carcinoma of the esophagus. J Clin Oncol 23: 2310-2317, 2005.
21. Saeki H, Morita M, Nakashima Y, Sonoda H, Hashimoto K, Egashira A, Oki E, Ohga T, Kakeji Y and Maehara Y: Neoadjuvant chemoradiotherapy for clinical stage II-III esophageal squamous cell carcinoma. Anticancer Res 31: 3073-3077, 2011.
22. Ota Y, Takagi Y, Osaka Y, Shinohara M, Hoshino S, Tsuchida A, Aoki T, Honda K and Yamada T: Usefulness of serum protein profiling for prediction of preoperative chemoradiosensitivity of esophageal cancer. Oncol Reports 18: 653-657, 2007.
23. Hayashida Y, Honda K, Osaka Y, Hara T, Umaki T, Tsuchida A, Aoki T, Hirohashi S and Yamada T: Possible prediction of chemoradiosensitivity of esophageal cancer by serum protein profiling. Clin Cancer Res 11: 8042-8047, 2005.
24. Osaka Y, Shinohara M, Hoshino S, Ogata T, Takagi Y, Tsuchida A and Aoki T: Phase II study of combined chemotherapy with docetaxel, CDDP and 5-FU for highly advanced esophageal cancer. Anticancer Res 31: 633-638, 2011.
25. van Heijl M, van Lanschot JJ, Koppert LB, van Berge Henegouwen MI, Muller K, Steyerberg EW, van Dekken H, Wijnhoven BP, Tilanus HW, Richel DJ, Busch OR, Bartelsman JF, Koning CC, Offerhaus GJ and van der Gaast A: Neoadjuvant chemoradiation followed by surgery versus surgery alone for patients with adenocarcinoma or squamous cell carcinoma of the esophagus (CROSS). BMC Surg 8: 21, 2008.
26. van Meerten E, Muller K, Tilanus HW, Siersema PD, Eijkenboom WM, van Dekken H, Tran TC and van der Gaast A: Neoadjuvant concurrent chemoradiation with weekly paclitaxel and carboplatin for patients with oesophageal cancer: A phase II study. Br J Cancer 94: 1389-1394, 2006.
27. Mizumoto M, Sugahara S, Nakayama H, Hashii H, Nakahara A, Terashima H, Okumura T, Tsuboi K, Tokuuye K and Sakurai H: Clinical results of proton-beam therapy for locoregionally advanced esophageal cancer. Strahlen Onkol 186: 482-488, 2010.
28. Nicolini G, Ghosh-Laskar S, Shrivastava SK, Banerjee S, Chaudhary S, Agarwal JP, Munshi A, Clivio A, Fogliata A, Mancosu P, Vanetti E and Cozzi L: Volumetric Modulation Arc Radiotherapy With Flattening Filter-Free Beams Compared With Static Gantry IMRT and 3D Conformal Radiotherapy for Advanced Esophageal Cancer: A Feasibility Study. Int J Radiat Oncol Biol Phys 84: 553-560, 2012.
29. Cunningham D, Allum WH, Stenning SP, Thompson JN, Van de Velde CJ, Nicolson M, Scarffe JH, Lofts FJ, Falk SJ, Iveson TJ, Smith DB, Langley RE, Verma M, Weeden S, Chua YJ and Participants MT: Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med 355: 11-20, 2006.
30. Ychou M, Boige V, Pignon JP, Conroy T, Bouche O, Lebreton G, Ducourtieux M, Bedenne L, Fabre JM, Saint-Aubert B, Geneve J, Lasser P and Rougier P: Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: An FNCLCC and FFCD multicenter phase III trial. J Clin Oncol 29: 1715-1721, 2011.
31. Akiyama H, Tsurumaru M, Udagawa H and Kajiyama Y: Radical lymph node dissection for cancer of the thoracic esophagus. Ann Surg 220: 364-372; discussion 372-373, 1994.
32. Watanabe H, Kato H and Tachimori Y: Significance of extended systemic lymph node dissection for thoracic esophageal carcinoma in Japan. Recent Results Cancer Res 155: 123-133, 2000.
33. Bedenne L, Michel P, Bouche O, Milan C, Mariette C, Conroy T, Pezet D, Roullet B, Seitz JF, Herr JP, Paillot B, Arveux P, Bonnetain F and Binquet C: Chemoradiation followed by surgery compared with chemoradiation alone in squamous cancer of the esophagus: FFCD 9102. J Clin Oncol 25: 1160-1168, 2007.
34. Swisher SG, Winter KA, Komaki RU, Ajani JA, Wu TT, Hofstetter WL, Konski AA and Willett CG: A phase II study of a paclitaxelbased chemoradiation regimen with selective surgical salvage for resectable locoregionally advanced esophageal cancer: initial reporting of RTOG 0246. Int J Radiat Oncol Biol Phys 82: 1967-1972, 2012.